Citigroup Initiates Coverage On Ascendis Pharma with Buy Rating, Announces Price Target of $187
Citigroup analyst David Lebowitz initiates coverage on Ascendis Pharma (NASDAQ:ASND) with a Buy rating and announces Price Target of $187.
Oppenheimer Upgrades Ascendis Pharma to Outperform, Announces $170 Price Target
Oppenheimer analyst Leland Gershell upgrades Ascendis Pharma (NASDAQ:ASND) from Perform to Outperform and announces $170 price target.
Where Ascendis Pharma Stands With Analysts
Over the past 3 months, 4 analysts have published their opinion on Ascendis Pharma (NASDAQ:ASND) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.
Ascendis Pharma’s Growth Hormone Deficiency Med Scores European Approval
The European Commission (EC) has granted marketing authorization to Ascendis Pharma A/S's (NASD
Cowen & Co. Initiates Coverage On Ascendis Pharma with Market Perform Rating, Announces Price Target of $136
Cowen & Co. analyst Yaron Werber initiates coverage on Ascendis Pharma (NASDAQ:ASND) with a Market Perform rating and announces Price Target of $136.
Ascendis’ Hypoparathyroidism Candidate Shows Durable Benefit At 84 Weeks
Ascendis Pharma A/S (NASDAQ:ASND) announced topline results from Week 84 of its Phase 2 PaTH Forward Trial of its TransCon PTH…
SVB Leerink Maintains Outperform on Ascendis Pharma, Raises Price Target to $190
SVB Leerink analyst Joseph Schwartz maintains Ascendis Pharma (NASDAQ:ASND) with a Outperform and raises the price target from $182 to $190.
Earnings Scheduled For November 10, 2021
Companies Reporting Before The Bell
• LumiraDx (NASDAQ:LMDX) is projected to report quarterly loss at $0.24 per share on revenue of $94.32 million.